Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Selfreport Questionnaire and Neuroimaging Biomarkers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: Subjective cognitive decline (SCD) may be the first symptomaticstage of Alzheimer's disease (AD). Hence, a screening tool to characterize the patients'complaints and assess the risk of AD is required. We investigated the SCD neuroimagingbiomarker distributions and the relevance between the self-report questionnaire andAlzheimer's pathologic changes. Methods: Individuals aged 50 and above with consistent cognitive complaints withoutany objective cognitive impairments were eligible for the study. The newly developedquestionnaire consisted of 2 parts; 10 questions translated from the ‘SCD-plus criteria’and a Korean version of the cognitive failure questionnaire by Broadbent. All the subjectsunderwent physical examinations such as blood work, detailed neuropsychological tests,the self-report questionnaire, brain magnetic resonance imagings, and florbetaben positronemission tomography (PET) scans. Amyloid PET findings were interpreted using both visualrating and quantitative analysis. Group comparisons and association analysis were performedusing SPSS (version 18.0). Results: A total of 31 participants with SCD completed the study and 25.8% showedpositive amyloid depositions. The degree of periventricular white matter hyperintensities(WMH) and hippocampal atrophy were more severe in amyloid-positive SCDs compared tothe amyloid-negative group. In the self-reported questionnaire, the ‘informant's report adecline’ and ‘symptom's onset after 65 years of age’ were associated with more Alzheimer'spathologic changes. Conclusions: Amyloid-positive SCDs differed from amyloid-negative SCDs on WMH,hippocampal atrophy, and a few self-reported clinical features, which gave clues on theprediction of AD pathology.
Abstract
Background and Purpose: Subjective cognitive decline (SCD) may be the first symptomaticstage of Alzheimer's disease (AD). Hence, a screening tool to characterize the patients'complaints and assess the risk of AD is required. We investigated the SCD neuroimagingbiomarker distributions and the relevance between the self-report questionnaire andAlzheimer's pathologic changes. Methods: Individuals aged 50 and above with consistent cognitive complaints withoutany objective cognitive impairments were eligible for the study. The newly developedquestionnaire consisted of 2 parts; 10 questions translated from the ‘SCD-plus criteria’and a Korean version of the cognitive failure questionnaire by Broadbent. All the subjectsunderwent physical examinations such as blood work, detailed neuropsychological tests,the self-report questionnaire, brain magnetic resonance imagings, and florbetaben positronemission tomography (PET) scans. Amyloid PET findings were interpreted using both visualrating and quantitative analysis. Group comparisons and association analysis were performedusing SPSS (version 18.0). Results: A total of 31 participants with SCD completed the study and 25.8% showedpositive amyloid depositions. The degree of periventricular white matter hyperintensities(WMH) and hippocampal atrophy were more severe in amyloid-positive SCDs compared tothe amyloid-negative group. In the self-reported questionnaire, the ‘informant's report adecline’ and ‘symptom's onset after 65 years of age’ were associated with more Alzheimer'spathologic changes. Conclusions: Amyloid-positive SCDs differed from amyloid-negative SCDs on WMH,hippocampal atrophy, and a few self-reported clinical features, which gave clues on theprediction of AD pathology.
참고문헌 (28)
- Reisberg B, "The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease", Alzheimers Dement, 4, pp.S98~S108 (2008)
- Jessen F, "A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease", Alzheimers Dement, 10, pp.844~852 (2014)
- 홍윤정, "Subjective Cognitive Decline and Alzheimer’s Disease Spectrum Disorder", Dementia and Neurocognitive Disorders(대한치매학회지), 16(2), pp.40~47 (2017), 대한치매학회[DOI]
- Sperling RA, "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease", Alzheimers Dement, 7, pp.280~292 (2011)
- Buckley RF, "A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease", J Mol Neurosci, 60, pp.354~361 (2016)
- van Harten AC, "Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints", Alzheimers Dement, 9, pp.481~487 (2013)
- Hong YJ, "Predictors of clinical progression of subjective memory impairment in elderly subjects: data from the Clinical Research Centers for Dementia of South Korea (CREDOS)", Dement Geriatr Cogn Disord, 40, pp.158~165 (2015)
- Risacher SL, "APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern", Alzheimers Dement, 11, pp.1417~1429 (2015)
- Zwan MD, "Subjective memory complaints in APOEε4 carriers are associated with high amyloid-β burden", J Alzheimers Dis, 49, pp.1115~1122 (2016)
- Morris JC, "The clinical dementia rating (CDR): current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Broadbent DE, "The cognitive failures questionnaire (CFQ) and its correlates", Br J Clin Psychol, 21, pp.1~16 (1982)
- Noh Y, "A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities", J Stroke Cerebrovasc Dis, 23, pp.636~642 (2014)
- Scheltens P, "Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates", J Neurol Neurosurg Psychiatry, 55, pp.967~972 (1992)
- Becker GA, "PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains", J Nucl Med, 54, pp.723~731 (2013)
- Barthel H, "Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study", Lancet Neurol, 10, pp.424~435 (2011)
- Kang Y, "Seoul Neuropsychological Screening Battery (SNSB-II). 2nd ed", Human Brain Research & Consulting Co, ~ (2012)
- Han C, "An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: demographic influence and population-based norms (the AGE study)", Arch Gerontol Geriatr, 47, pp.302~310 (2008)
- Jack CR Jr, "Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers", Lancet Neurol, 12, pp.207~216 (2013)
- Claus JJ, "Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: validation in a large memory clinic population", Eur Radiol, 27, pp.3147~3155 (2017)
- Kern S, "Prevalence of preclinical Alzheimer disease: comparison of current classification systems", Neurology, 90, pp.e1682~e1691 (2018)
- Rowe CC, "Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging", Neurobiol Aging, 31, pp.1275~1283 (2010)
- Kandel BM, "White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration", Alzheimers Dement (Amst), 4, pp.18~27 (2016)
- Valech N, "Informants' perception of subjective cognitive decline helps to discriminate preclinical Alzheimer's disease from aging", J Alzheimers Dis, 48(Suppl 1), pp.S87~S98 (2015)
- Carr DB, "The value of informant versus individual's complaints of memory impairment in early dementia", Neurology, 55, pp.1724~1726 (2000)
- Okonkwo OC, "Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease", Arch Neurol, 67, pp.688~696 (2010)
- Rabin LA, "Predicting Alzheimer's disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties", J Am Geriatr Soc, 60, pp.1128~1134 (2012)
- Caselli RJ, "Subjective cognitive decline: self and informant comparisons", Alzheimers Dement, 10, pp.93~98 (2014)
- Hollands S, "Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults", J Alzheimers Dis, 43, pp.677~686 (2015)